Five Oceans Advisors Sells 29 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Five Oceans Advisors lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) by 4.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 609 shares of the medical research company’s stock after selling 29 shares during the period. Five Oceans Advisors’ holdings in Thermo Fisher Scientific were worth $323,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in TMO. Halpern Financial Inc. grew its holdings in shares of Thermo Fisher Scientific by 307.7% during the 3rd quarter. Halpern Financial Inc. now owns 53 shares of the medical research company’s stock worth $27,000 after purchasing an additional 40 shares in the last quarter. Coppell Advisory Solutions LLC acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth $33,000. Live Oak Investment Partners acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth $36,000. Tyler Stone Wealth Management acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth $37,000. Finally, Indiana Trust & Investment Management CO acquired a new stake in shares of Thermo Fisher Scientific during the 3rd quarter worth $38,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the transaction, the senior vice president now directly owns 12,901 shares in the company, valued at approximately $7,250,362. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the transaction, the senior vice president now owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the completion of the transaction, the chief executive officer now directly owns 49,155 shares of the company’s stock, valued at approximately $27,311,992.65. The disclosure for this sale can be found here. In the last three months, insiders have sold 50,277 shares of company stock worth $28,513,384. 0.32% of the stock is owned by company insiders.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Barclays lowered Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and raised their price objective for the company from $475.00 to $555.00 in a research note on Wednesday, January 24th. Robert W. Baird reiterated an “outperform” rating and issued a $670.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, December 14th. Royal Bank of Canada increased their target price on Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. HSBC started coverage on Thermo Fisher Scientific in a research report on Monday, December 18th. They issued a “buy” rating and a $610.00 target price for the company. Finally, Raymond James increased their target price on Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. Five research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $599.00.

View Our Latest Stock Analysis on Thermo Fisher Scientific

Thermo Fisher Scientific Trading Down 1.5 %

Shares of Thermo Fisher Scientific stock opened at $568.75 on Tuesday. The stock has a market capitalization of $216.87 billion, a PE ratio of 37.39, a price-to-earnings-growth ratio of 2.44 and a beta of 0.80. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.39 and a current ratio of 1.75. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $603.82. The stock has a 50 day moving average price of $566.95 and a two-hundred day moving average price of $521.68.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last announced its earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.64 by $0.03. The company had revenue of $10.89 billion for the quarter, compared to analysts’ expectations of $10.73 billion. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. Thermo Fisher Scientific’s quarterly revenue was down 4.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $5.40 earnings per share. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 15th. Investors of record on Friday, March 15th will be paid a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend is Thursday, March 14th. Thermo Fisher Scientific’s payout ratio is presently 10.10%.

Thermo Fisher Scientific Company Profile

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Recommended Stories

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.